Welcome to the e-CCO Library!

P021: Aryl hydrocarbon receptor controls ILC3/ILC1 immunity in a colitis model of 2, 4,6-trinitrobenzene sulphonic acid
Year: 2018
Source: ECCO '18 Vienna
Authors:

X. Zhao*, H. Zhang

Created: Thursday, 21 February 2019, 9:14 AM
P021: Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course
Year: 2021
Source: ECCO'21 Virtual
Authors: Heredia, M.(1);Charrout, M.(2);Klomberg, R.(3);Aardoom, M.(3);Jongsma, M.(3);Kemos, P.(4);van Haaften, D.(1);Tuk, B.(1);van Berkel, L.(1);Bley Folly, B.(1);Mahfouz, A.(2);Reinders, M.(2);Ruemmele, F.(5);Croft, N.(4);Escher, J.(3);de Ridder, L.(3);Samsom, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P021: Inflammatory monocytes are key regulators of colonic inflammation in murine and human IBD
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G.-R. Jones*1, P. Cook2, A. MacDonald2, T. Fenton2, A. Kelly2, M. Travis2, S. Campbell3

Created: Friday, 22 February 2019, 9:49 AM
P021: Microbial metabolite receptors as mediators of pathogenic processes in Inflammatory Bowel Disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Spathakis, M.(1,2)*;Dovrolis, N.(1,2);Tarapatzi, G.(1,2);Filidou , E.(1,2);Kandilogiannakis, L.(1,2);Valatas, V.(1,3);Drygiannakis, I.(3);Manolopoulos, V.G.(1,2);Kolios, G.(1,2);Arvanitidis, K.(1,2);Vradelis, S.(4);
Created: Friday, 14 July 2023, 10:48 AM
P021: Utility of therapeutic anti-TNF drug monitoring in hospitals with different degree of experience in the treatment of inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vila M.*1, Bahi A.1, Miquel J.O.2, Busquets D.3, Salό J.2, Aldeguer X.3

Created: Wednesday, 20 February 2019, 10:36 AM
P021: Vitamin D receptor-dependent protective effect of moderate hypoxia in a mouse colitis model Running title: Hypoxia prevents mouse colitis through VDR
Year: 2022
Source: ECCO'22
Authors: Wang, Z.(1);Hong, Y.(2);Hong, L.(3);Changzhi, H.(4);Jiaming, Q.(3);
Created: Friday, 11 February 2022, 3:52 PM
P022 Impact of increasing disease symptom concordance between patients with inflammatory bowel disease and their physicians: insights from US, France, Germany, Italy, Spain and UK (5EU)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Kershaw1, R. Wild1, R. Lukanova1, S. Bruce Wirta2, M. Sikirica3

Created: Thursday, 30 January 2020, 10:12 AM
P022: A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Łukawska, A.(1)*;Mulak, A.(1);
Created: Friday, 14 July 2023, 10:48 AM
P022: Galectin-3, galectin-9, and galectin-3 binding protein in patients with inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Cibor*1, K. Szczeklik2, D. Owczarek1, T. Mach1

Created: Friday, 22 February 2019, 9:41 AM
P022: MET deletion in MRP8+ neutrophils is protective during DDS-induced colitis via Th17 pathway
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Stakenborg M., Meroni E., Goverse G., Matteoli G.

Created: Wednesday, 20 February 2019, 10:36 AM
P022: Parthenolide enhances the efficacy of anti-tumour effect of balsalazide in human colon cancer cells and colitis-associated colorectal cancer by blockade of NF-kB activation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. S. Seo1, S.-L. Kim2, S. W. Kim*2

Created: Friday, 22 February 2019, 9:49 AM
P022: Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn’s disease early postsurgical recurrence.
Year: 2021
Source: ECCO'21 Virtual
Authors: Suau, R.(1);Garcia-Jaraquemada, A.(2);Lorén, V.(1);Torres, P.(2);Jou, E.(2);Llaves, M.(2);Aterido, A.(3);Julià, T.(3);Zabana, Y.(4);Lozano, J.J.(5);Domènech, E.(6);Mañosa, M.(6);Manyé, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P022: Severe disease activity in UC is associated with mucosal hypoxia measured endoscopically
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R. Rowan1*, E. Brown2, E. Ryan3, C. Taylor2, G.A. Doherty4

Created: Thursday, 21 February 2019, 9:14 AM
P022: Transcriptional biomarkers for vedolizumab therapy response in patients with moderate to severe Ulcerative Colitis.
Year: 2022
Source: ECCO'22
Authors: Arosa García, L.(1);Camba-Gómez, M.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto , M.(2);Nieto-García , L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta , M.(2);Conde-Aranda, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P023 Identification of regulated mechanistic pathways and genes to protect intestinal barrier injury by larazotide acetate in an IBD microenvironment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Jin1, J. Madan2, K. Radha B2, B. Anthony3

Created: Thursday, 30 January 2020, 10:12 AM
P023: A resting state fMRI study in patients with active Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Thapaliya1, S. Eldeghaidy2, S. J. Radford1, S. Francis2, G. Moran*1

Created: Friday, 22 February 2019, 9:41 AM
P023: Development of methods to investigate effects of narrow spectrum kinase inhibitors on cellular phosphorylation of kinase substrates
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Sirohi*, M. Foster, M. Fyfe, Y. Solanke, S. Webber, C. Walshe

Created: Friday, 22 February 2019, 9:49 AM
P023: Fatigue in quiescent inflammatory bowel disease is associated with low GM-CSF levels and metabolomic alterations
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Borren N.*1,2, Goel G.3,4, Lassen K.1, Devaney K.1, Cleland T.1, Garber J.1,4, Khalili H.1,4, Yajnik V.1,4, Xavier R.1,4, Ananthakrishnan A.1,4

Created: Wednesday, 20 February 2019, 10:36 AM
P023: Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Suau, R.(1,2)*;Pardina, E.(3);López-Tejero, M.D.(3);Lorén, V.(1,2);Zabana, Y.(2,4);Llaves, M.(1);Cordobilla, B.(3);Cañete, F.(2,5);Guasch, M.(6);Ricart-Jané, D.(3);Mañosa, M.(2,5);Domènech, E.(2,5);Domingo, J.C.(3);Manyé, J.(1,2);
Created: Friday, 14 July 2023, 10:48 AM